BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 25199984)

  • 1. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
    Sewastianik T; Prochorec-Sobieszek M; Chapuy B; Juszczyński P
    Biochim Biophys Acta; 2014 Dec; 1846(2):457-67. PubMed ID: 25199984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
    Petrich AM; Nabhan C; Smith SM
    Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC and aggressive B-cell lymphomas.
    Slack GW; Gascoyne RD
    Adv Anat Pathol; 2011 May; 18(3):219-28. PubMed ID: 21490439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.
    Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Arakawa F; Niino D; Ohshima K
    Pathol Int; 2015 Oct; 65(10):519-27. PubMed ID: 26224092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
    Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
    Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Doublehit lymphomas -  review of the literature and case report].
    Smardová J; Moulis M; Lišková K; Koptíková J; Hrabálková R; Klusáková J
    Klin Onkol; 2014; 27(1):24-32. PubMed ID: 24635434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
    Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
    Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
    Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
    J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
    Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
    J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel five-way translocation, t(3;9;13;8;14)(q27;p13;q32;q24;q32), with concurrent MYC and BCL6 rearrangements in a primary bone marrow B-cell lymphoma.
    Yamamoto K; Matsuoka H; Yakushijin K; Funakoshi Y; Okamura A; Hayashi Y; Minami H
    Cancer Genet; 2011 Sep; 204(9):501-6. PubMed ID: 22018272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?
    Mationg-Kalaw E; Tan LH; Tay K; Lim ST; Tang T; Lee YY; Tan SY
    Histopathology; 2012 Dec; 61(6):1214-8. PubMed ID: 23171357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma.
    Rosenthal A; Younes A
    Blood Rev; 2017 Mar; 31(2):37-42. PubMed ID: 27717585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
    Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
    Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-hit B-cell lymphomas.
    Aukema SM; Siebert R; Schuuring E; van Imhoff GW; Kluin-Nelemans HC; Boerma EJ; Kluin PM
    Blood; 2011 Feb; 117(8):2319-31. PubMed ID: 21119107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.